Intellia Therapeutics (NTLA) is Initiated by Credit Suisse to Outperform, Price Target at $39

Intellia Therapeutics (NTLA) was Initiated by Credit Suisse to “Outperform” and the brokerage firm has set the Price Target at $39. Credit Suisse advised their investors in a research report released on May 31, 2016.

Intellia Therapeutics

Leave a Reply

Intellia Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intellia Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.